XERIS BIOPHARMA HOLDINGS INC (XERS) — insider trading
Health Care · NASDAQ
XERIS BIOPHARMA HOLDINGS INC (XERS) has 37 reported SEC Form 4 insider transactions in our data, including 21 open-market sales among the most recent 37 (latest 2026-10-01).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-10-01 | Pieper Steven | Officer (See Remarks) | Open-market sale | 5,000 | $9.41 | $47.0K | Form 4 |
| 2026-10-01 | McCulloch Kevin | Officer (See Remarks) | Open-market sale | 15,000 | $9.41 | $141.1K | Form 4 |
| 2026-10-01 | Hecht Beth | Officer (See Remarks) | Open-market sale | 16,666 | $9.41 | $156.8K | Form 4 |
| 2026-09-28 | McCulloch Kevin | Officer (See Remarks) | Open-market sale | 25,000 | $10.00 | $250.0K | Form 4 |
| 2026-09-01 | Pieper Steven | Officer (See Remarks) | Open-market sale | 5,000 | $8.50 | $42.5K | Form 4 |
| 2026-09-01 | McCulloch Kevin | Officer (See Remarks) | Open-market sale | 15,000 | $8.49 | $127.3K | Form 4 |
| 2026-09-01 | Hecht Beth | Officer (See Remarks) | Open-market sale | 16,666 | $8.49 | $141.4K | Form 4 |
| 2026-08-12 | Pieper Steven | Officer (See Remarks) | Open-market sale | 5,000 | $8.50 | $42.5K | Form 4 |
| 2026-08-03 | Hecht Beth | Officer (See Remarks) | Open-market sale | 16,666 | $8.01 | $133.6K | Form 4 |
| 2026-08-03 | McCulloch Kevin | Officer (See Remarks) | Open-market sale | 15,000 | $8.02 | $120.2K | Form 4 |
| 2026-08-01 | Shannon John Patrick Jr | Director, Officer (See Remarks) | Shares withheld for taxes / exercise cost | 36,645 | $8.08 | $296.1K | Form 4 |
| 2026-08-01 | McCulloch Kevin | Officer (See Remarks) | Shares withheld for taxes / exercise cost | 21,918 | $8.08 | $177.1K | Form 4 |
| 2026-07-07 | Pieper Steven | Officer (See Remarks) | Open-market sale | 27,600 | $8.52 | $235.3K | Form 4 |
| 2026-07-06 | Pieper Steven | Officer (See Remarks) | Open-market sale | 17,400 | $8.50 | $147.9K | Form 4 |
| 2026-07-01 | Hecht Beth | Officer (See Remarks) | Open-market sale | 16,666 | $8.03 | $133.9K | Form 4 |
| 2026-07-01 | McCulloch Kevin | Officer (See Remarks) | Open-market sale | 90,000 | $8.03 | $722.5K | Form 4 |
| 2026-07-01 | KREHER NERISSA | Director | Grant / award / vesting (derivative) | 37,910 | $8.00 | $303.3K | Form 4 |
| 2026-07-01 | KREHER NERISSA | Director | Grant / award / vesting | 33,582 | — | $0 | Form 4 |
| 2026-06-04 | Brady James Aloysius | Director | Grant / award / vesting (derivative) | 32,996 | $6.15 | $202.9K | Form 4 |
| 2026-06-04 | Brady James Aloysius | Director | Grant / award / vesting | 24,193 | — | $0 | Form 4 |
| 2026-06-04 | JOHNSON JOHN | Director | Grant / award / vesting (derivative) | 32,996 | $6.15 | $202.9K | Form 4 |
| 2026-06-04 | JOHNSON JOHN | Director | Grant / award / vesting | 24,193 | — | $0 | Form 4 |
| 2026-06-04 | JOHNSON JOHN | Director | Open-market sale | 15,000 | $6.09 | $91.4K | Form 4 |
| 2026-06-04 | BORMANN-KENNEDY BARBARA-JEAN ANNE | Director | Grant / award / vesting (derivative) | 32,996 | $6.15 | $202.9K | Form 4 |
| 2026-06-04 | BORMANN-KENNEDY BARBARA-JEAN ANNE | Director | Grant / award / vesting | 24,193 | — | $0 | Form 4 |
| 2026-06-04 | BORMANN-KENNEDY BARBARA-JEAN ANNE | Director | Open-market sale | 16,000 | $6.09 | $97.5K | Form 4 |
| 2026-06-04 | HALKUFF DAWN | Director | Grant / award / vesting (derivative) | 32,996 | $6.15 | $202.9K | Form 4 |
| 2026-06-04 | HALKUFF DAWN | Director | Grant / award / vesting | 24,193 | — | $0 | Form 4 |
| 2026-06-04 | HALKUFF DAWN | Director | Open-market sale | 20,000 | $6.09 | $121.9K | Form 4 |
| 2026-06-04 | PERSKY MARLA | Director | Grant / award / vesting (derivative) | 32,996 | $6.15 | $202.9K | Form 4 |
| 2026-06-04 | PERSKY MARLA | Director | Grant / award / vesting | 24,193 | — | $0 | Form 4 |
| 2026-06-04 | Kong Garheng | Director | Grant / award / vesting (derivative) | 32,996 | $6.15 | $202.9K | Form 4 |
| 2026-06-04 | Kong Garheng | Director | Grant / award / vesting | 24,193 | — | $0 | Form 4 |
| 2026-06-03 | PERSKY MARLA | Director | Open-market sale | 15,500 | $5.90 | $91.4K | Form 4 |
| 2026-06-01 | Hecht Beth | Officer (See Remarks) | Open-market sale | 16,667 | $6.06 | $101.0K | Form 4 |
| 2026-05-01 | Hecht Beth | Officer (See Remarks) | Open-market sale | 16,667 | $6.23 | $103.8K | Form 4 |
| 2026-04-01 | Hecht Beth | Officer (See Remarks) | Open-market sale | 16,667 | $5.99 | $99.9K | Form 4 |
Ask the chat about XERS's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: XERIS BIOPHARMA HOLDINGS INC (XERS).
Last updated 2026-10-01 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.